Innate Pharma S.A. Price & Performance (IPHA)

Innate Pharma's stock has risen by 26% in the past month, despite a 35% revenue decline last year. Analysts predict 39% annual growth over the next three years, but this trails the biotech industry’s expected 51%. The company's elevated price-to-sales ratio raises concerns about potential overvaluation.1

Innate Pharma will host a conference call on March 27 to discuss its 2024 financial results. Key executives, including CEO Jonathan Dickinson, will address performance updates. The webcast will be available online, with a recording accessible for 90 days post-event, highlighting transparency in investor relations.2

Innate Pharma will present at the Leerink Partners 2025 Global Healthcare Conference in Miami. The company plans to showcase its innovative cancer immunotherapy pipeline, including its ANKET platform and partnerships with AstraZeneca and Sanofi. This event underscores its efforts to strengthen its global presence.3